Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5‑Lipoxygenase

• Published in: ACS medicinal chemistry letters Vol. 10; no. 10; pp. 1415 - 1422
• Main Authors: Sinha, Shweta, Manju, S. L, Doble, Mukesh
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 10.10.2019; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Letter; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; synthesis; hybrid; thiazole; design; pseudoperoxidase; pharmacophore; 5-LOX; Chalcone; DISCOVERY; POTENT; BIOLOGICAL EVALUATION; INHIBITORS; DERIVATIVES
• ISSN: 1948-5875; 1948-5875
• DOI: 10.1021/acsmedchemlett.9b00193

A hybrid pharmacophore approach is used to design and synthesize novel chalcone-thiazole hybrid molecules. Herein, thiazole has been hybridized with chalcone to obtain a new class of 5-LOX inhibitors. In vitro biological evaluation showed that most of the compounds were better 5-LOX inhibitors than the positive control, Zileuton (IC50 = 1.05 ± 0.03 μM). The best compounds in the series, namely, 4k, 4n, and 4v (4k: IC50 = 0.07 ± 0.02 μM, 4n: IC50 = 0.08 ± 0.05 μM, 4v: 0.12 ± 0.04 μM) are found to be 10 times more active than previously reported 2-amino thiazole (2m: IC50 = 0.9 ± 0.1 μM) by us. Further, 4k has redox (noncompetitive) while 4n and 4v act through a competitive inhibition mechanism. SAR indicated that the presence of methoxy/methyl either in the vicinity of chalcone or both thiazole and chalcone contributed to the synergistic inhibitory effect.